EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Proteolysis-Targeting Chimeras Induce Ferroptosis in Cancer: From Mechanism to Clinical Application

Na Zeng, Xing-Yu Zhong, Si-Han Zhang, Mei-Cheng Liu, Qi-Dong Xia, Xiao Yu, Shao-Gang Wang

Pharmacological Research · 2026

DOI: 10.1016/j.phrs.2026.108141 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026. Verfasst von Na Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, …. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ferroptosis, an iron-dependent cell death driven by lipid peroxidation, is a crucial tumor suppression mechanism and promising therapeutic avenue, especially for resistant cancers. However, its clinical translation is hindered by complex regulatory networks, compensatory pathways, and a lack of selective modulators. The advent of Proteolysis-Targeting Chimeras (PROTACs) presents a groundbreaking opportunity to precisely manipulate this pathway. This review systematically explores leveraging PROTAC technology to induce ferroptosis. We first delineate the core regulatory axes, including GPX4, FSP1, and DHODH pathways, and their crosstalk with oncogenic signaling and the tumor microenvironment. The focus then shifts to rational PROTAC design strategies targeting these key nodes, summarizing current preclinical proof-of-concept efforts, primarily against GPX4. Despite this promise, challenges remain, including PROTAC druggability, the dual role of ferroptosis, and compensatory resistance. Future strategies to overcome these hurdles involve developing multi-target degraders, intelligent drug delivery systems, and synergistic combinations with conventional and immunotherapies. The integration of computational tools and AI for accelerated design is also highlighted. In conclusion, PROTAC technology represents a versatile platform for reactivating ferroptosis, holding immense potential to overcome drug resistance and treat refractory cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisNeoplasmsAntineoplastic AgentsHumansAnimalsProteolysis Targeting ChimeraProteolysis

Stichwörter der Autor:innen

Cancer TherapyDrug DesignFerroptosisPROTACProteolysis-targeting chimeras

Substanzen

Proteolysis Targeting ChimeraAntineoplastic Agents

Autor:innen und Institutionen

  • Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan 430030, China.
  • Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan 430030, China. Electronic address: qidongxia_md@163.com.
  • Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan 430030, China. Electronic address: yujiuhu@163.com.
  • Department and Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1095 Jiefang Avenue, Wuhan 430030, China. Electronic address: sgwangtjm@163.com.

Zitieren

APA

Zeng, N., Zhong, X. Y., Zhang, S. H., Liu, M. C., Xia, Q. D., Yu, X., & Wang, S. G. (2026). Proteolysis-Targeting Chimeras Induce Ferroptosis in Cancer: From Mechanism to Clinical Application. Pharmacological Research. https://doi.org/10.1016/j.phrs.2026.108141

Vancouver

Zeng N, Zhong XY, Zhang SH, Liu MC, Xia QD, Yu X, et al. Proteolysis-Targeting Chimeras Induce Ferroptosis in Cancer: From Mechanism to Clinical Application. Pharmacological Research. 2026. doi:10.1016/j.phrs.2026.108141

BibTeX
@article{Zeng2026,
  author = {Zeng, Na and Zhong, Xing-Yu and Zhang, Si-Han and Liu, Mei-Cheng and Xia, Qi-Dong and Yu, Xiao and Wang, Shao-Gang},
  title = {Proteolysis-Targeting Chimeras Induce Ferroptosis in Cancer: From Mechanism to Clinical Application},
  journal = {Pharmacological Research},
  year = {2026},
  doi = {10.1016/j.phrs.2026.108141}
}
Kostenlos starten →